Retour
54
16
53
Fourchette du Jour
1,70 €
1,75 €
Fourchette 52 Semaines
1,43 €
2,35 €
Volume
29
Moyenne 50J / 200J
1,79 €
/
1,85 €
Clôture Précédente
1,70 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (627 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 1,3 | 0,4 |
| P/B | 0,2 | 2,9 |
| ROE % | 19,6 | 3,7 |
| Net Margin % | 19,3 | 3,9 |
| Rev Growth 5Y % | 11,9 | 10,0 |
| D/E | 0,2 | 0,2 |
Objectif de Cours des Analystes
Aucune couverture d'analyste disponible
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2029 |
0,00 €
0,00 € – 0,00 €
|
17 B | 0 |
| FY2028 |
1,52 €
1,29 € – 1,72 €
|
15 B | 1 |
| FY2027 |
1,37 €
1,16 € – 1,54 €
|
14 B | 1 |
Points Clés
Revenue grew 11,91% annually over 5 years — strong growth
ROE of 19,61% — decent returns on equity
Net margin of 19,33% shows strong profitability
Debt/Equity of 0,22 — conservative balance sheet
Generating 1,33B in free cash flow
P/E of 1,26 — trading at a low valuation
Croissance
Revenue Growth (5Y)
11,91%
Revenue (1Y)0,14%
Earnings (1Y)-1,54%
FCF Growth (3Y)3,07%
Qualité
Return on Equity
19,61%
ROIC13,32%
Net Margin19,33%
Op. Margin22,65%
Sécurité
Debt / Equity
0,22
Current Ratio1,83
Interest Coverage89,14
Valorisation
P/E Ratio
1,26
P/B Ratio0,23
EV/EBITDA0,06
Dividend Yield0,06%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 0,14% | Revenue Growth (3Y) | 10,18% |
| Earnings Growth (1Y) | -1,54% | Earnings Growth (3Y) | 29,70% |
| Revenue Growth (5Y) | 11,91% | Earnings Growth (5Y) | 39,47% |
| Profitability | |||
| Revenue (TTM) | 13,76B | Net Income (TTM) | 2,66B |
| ROE | 19,61% | ROA | 10,30% |
| Gross Margin | 44,21% | Operating Margin | 22,65% |
| Net Margin | 19,33% | Free Cash Flow (TTM) | 1,33B |
| ROIC | 13,32% | FCF Growth (3Y) | 3,07% |
| Safety | |||
| Debt / Equity | 0,22 | Current Ratio | 1,83 |
| Interest Coverage | 89,14 | Dividend Yield | 0,06% |
| Valuation | |||
| P/E Ratio | 1,26 | P/B Ratio | 0,23 |
| P/S Ratio | 0,24 | PEG Ratio | -3,10 |
| EV/EBITDA | 0,06 | Dividend Yield | 0,06% |
| Market Cap | 3,35B | Enterprise Value | 180,04M |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 13,76B | 13,74B | 11,33B | 9,70B | 8,77B |
| Net Income | 2,66B | 2,70B | 1,58B | 988,10M | 702,99M |
| EPS (Diluted) | 1,46 | 1,49 | 0,87 | 0,54 | 0,40 |
| Gross Profit | 6,08B | 6,33B | 4,97B | 4,21B | 3,81B |
| Operating Income | 3,12B | 3,29B | 2,02B | 1,41B | 1,23B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 25,83B | 21,02B | 18,98B | 16,33B | 14,96B |
| Total Liabilities | 11,40B | 8,27B | 8,37B | 6,99B | 6,35B |
| Shareholders' Equity | 14,39B | 12,73B | 10,61B | 9,34B | 8,61B |
| Total Debt | 3,16B | 1,50B | 2,46B | 1,84B | 2,21B |
| Cash & Equivalents | 6,33B | 4,26B | 4,74B | 3,33B | 3,00B |
| Current Assets | 16,07B | 13,79B | 12,51B | 9,99B | 8,22B |
| Current Liabilities | 8,77B | 6,63B | 7,03B | 6,54B | 4,86B |
Scores de Stratégies
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
#240 of 824
#465 of 670
#113 of 710
Activité Récente
Entré
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entré
Contrarian Investing (David Dreman)
Mar 24, 2026
Entré
Defensive Investing (Benjamin Graham)
Mar 24, 2026